Main navigation

Enroll in the ALS Care Locator

Help the ALS community locate infusion services.

The ALS Care Locator can help:

Increase local awareness about your infusion center

Provide detailed search results about your infusion services

Once you enroll, you will receive an email confirming receipt of your information. A Mitsubishi Tanabe Pharma America, Inc. representative will contact you to validate your information and, once validated, your infusion service will be added to the ALS Care Locator.

(A separate enrollment must be submitted for each infusion center or home infusion service location.)

The ALS Care Locator is a directory with a number of functions, including a directory of infusion centers that treat ALS and which have opted-in to participate in the directory. This submission information is updated on a monthly basis.

Infusion centers listed in the directory are not affiliated with Mitsubishi Tanabe Pharma America, Inc. and do not pay to be on this list. No fees or remuneration of any kind have been or will be exchanged for participation in the ALS Care Locator. Inclusion of an infusion center in the ALS Care Locator does not constitute a referral, recommendation, endorsement, or verification of credentials, qualifications, or abilities of the infusion center listed. Similarly, the absence of an infusion center's name and information should not be construed as a negative comment from Mitsubishi Tanabe Pharma America, Inc. about the infusion center's credentials. qualifications, or abilities.

Mitsubishi Tanabe Pharma America, Inc., as well as its employees or agents, shall not be held liable for any damages or harm resulting from any use or reliance on information contained in the ALS Care Locator; and may modify, amend, remove or cancel the ALS Care Locator at any time without notice.

Important Safety Information

Hypersensitivity Reactions

Radicava® (edaravone) is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in Radicava®. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have been reported. Patients should be monitored carefully for hypersensitivity reactions, and if they occur, discontinue Radicava®, treat per standard of care, and monitor until the condition resolves.

Sulfite Allergic Reactions

Radicava® contains sodium bisulfite, and may cause allergic type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown, but occurs more frequently in asthmatic people.

Most Common Adverse Reactions

Most common adverse reactions (at least 10% and greater than placebo) are contusion, gait disturbance, and headache.

Pregnancy

Based on animal data, Radicava® may cause fetal harm.

Geriatric Use

No overall differences in safety or effectiveness were observed between patients 65 years of age and older and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Indication

Radicava® is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

RADICAVA, the RADICAVA logo, and the corporate symbol of Mitsubishi Tanabe Pharma America are registered trademarks of Mitsubishi Tanabe Pharma Corporation.
Searchlight Support is a registered trademark of Mitsubishi Tanabe Pharma America, Inc.
All other trademarks are property of their respective owners.